<DOC>
	<DOCNO>NCT00869986</DOCNO>
	<brief_summary>The purpose study test dirucotide safe effective treating patient relapse remit multiple sclerosis .</brief_summary>
	<brief_title>A Study Patients With Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Male female subject , 1850 year age 2 . Relapsingremitting multiple sclerosis ( RRMS ) accord `` Diagnostic criterion multiple sclerosis : 2005 revision McDonald Criteria '' ( Annals Neurology 58 : 840846 ) 3 . At least 2 year history MS trial entry 4 . Documented history 2 exacerbation 2 year prior trial entry 5 . Stable neurological status least 30 day first study drug administration 6 . Have EDSS 05.5 7 . If female , must either postmenopausal surgically sterilize ; use hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , duration study ; neither pregnant breastfeeding 8 . Willingness ability comply protocol duration study 9 . In Investigator 's opinion , subject must reliable , compliant , agree cooperate trial evaluation 10 . Subject must able willing give meaningful , write informed consent prior participation trial , accordance regulatory requirement 1 . Have Clinically Isolated Syndrome ( CIS ) , Secondary Progressive MS ( SPMS ) , Primary Progressive MS ( PPMS ) 2 . Any known malignancy , history malignancy , exclusion basal cell carcinoma 3 . Have active , clinically significant liver , renal bone marrow disease accompany significant laboratory abnormality range grade I define Common Toxicity Criteria ( CTC ) , 4 . Clinically significant ECG abnormality screen 5 . Have presence systemic disease , opinion investigator , might interfere subject safety , compliance evaluation condition study ( e.g . insulin dependent diabetes , lyme disease , clinically significant cardiac , hepatic , renal disease , Human Immunodeficiency Virus , Human TCell Lymphotrophic Virus Type1 ) 6 . Have current autoimmune disease , compromise immune function infection 7 . History allergic reaction glatiramer acetate 8 . Steroid therapy within 30 day prior first study specific procedure , treatment know used putative experimental MS treatment 9 . Therapy ÃŸinterferon , glatiramer acetate , statin , copaxone nonspecific phosphodiesterase inhibitor within 3 month prior first studyspecific test 10 . Therapy mitoxantrone , cyclophosphamide , methotrexate , azathioprine , immunomodulating ( e.g . IVIG ) immunosuppressive drug include recombinant nonrecombinant cytokine plasma exchange within 6 month prior performance first studyspecific test , exception corticosteroid ACTH relapse treatment 11 . Treatment time alter peptide ligand , cladribine , total lymphoid irradiation , monoclonal antibody treatment e.g . antiCD4 , antiCD52 , antiVLA4 , AntiCD20 , 12 . Any contraindication MRI , e.g . pacemaker know allergy Gadolinium DTPA 13 . Participation trial investigational agent within 90 day prior screen 14 . History alcohol drug abuse specify Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) within year screen 15 . Any medical , psychiatric condition could result subject able give fully inform consent , comply protocol requirement 16 . Any condition , Investigator 's opinion , make subject unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>